stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Shares outstanding
Celldex Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $66.4M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $77.8M. Over the past ten years it has ranged from $6.5M (fiscal 2015) to $66.4M (fiscal 2025) — the current reading is the highest in ten years. Celldex Therapeutics, Inc. ranks 195th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $66.4M | 3.15% |
| FY2024 | $64.4M | 32.91% |
| FY2023 | $48.4M | 3.33% |
| FY2022 | $46.9M | 9.37% |
| FY2021 | $42.9M | 44.64% |
| FY2020 | $29.6M | 104.32% |
| FY2019 | $14.5M | 38.93% |
| FY2018 | $10.4M | 21.84% |
| FY2017 | $8.6M | 26.61% |
| FY2016 | $6.8M | 4.57% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $77.8M | 16.94% |
| Mar 2026 | $66.6M | 0.22% |
| Dec 2025 | $66.4M | 0.00% |
| Sep 2025 | $66.4M | 0.04% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| PHVS Pharvaris N.V. compare | $68.1M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement